NO20052991D0 - Kinazolinforbindelser. - Google Patents

Kinazolinforbindelser.

Info

Publication number
NO20052991D0
NO20052991D0 NO20052991A NO20052991A NO20052991D0 NO 20052991 D0 NO20052991 D0 NO 20052991D0 NO 20052991 A NO20052991 A NO 20052991A NO 20052991 A NO20052991 A NO 20052991A NO 20052991 D0 NO20052991 D0 NO 20052991D0
Authority
NO
Norway
Prior art keywords
quinazoline
Prior art date
Application number
NO20052991A
Other languages
English (en)
Other versions
NO20052991L (no
Inventor
Andrew Austen Mortlock
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20052991D0 publication Critical patent/NO20052991D0/no
Publication of NO20052991L publication Critical patent/NO20052991L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20052991A 2002-12-24 2005-06-17 Kinazolinforbindelser. NO20052991L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02293239 2002-12-24
PCT/GB2003/005636 WO2004058752A1 (en) 2002-12-24 2003-12-22 Quinazoline compounds

Publications (2)

Publication Number Publication Date
NO20052991D0 true NO20052991D0 (no) 2005-06-17
NO20052991L NO20052991L (no) 2005-07-19

Family

ID=32668916

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052991A NO20052991L (no) 2002-12-24 2005-06-17 Kinazolinforbindelser.

Country Status (12)

Country Link
US (1) US7407946B2 (no)
EP (1) EP1575946A1 (no)
JP (1) JP2006516138A (no)
KR (1) KR20050087863A (no)
CN (1) CN1753889A (no)
AU (1) AU2003290322A1 (no)
BR (1) BR0317680A (no)
CA (1) CA2508921A1 (no)
MX (1) MXPA05006920A (no)
NO (1) NO20052991L (no)
WO (1) WO2004058752A1 (no)
ZA (1) ZA200504828B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2290529T3 (es) * 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
CN1809557B (zh) 2003-04-16 2012-07-04 阿斯利康(瑞典)有限公司 化合物
ATE401080T1 (de) * 2003-06-02 2008-08-15 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
EP1802591B1 (en) 2004-10-12 2012-01-11 AstraZeneca AB Quinazoline derivatives
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1785420A1 (en) * 2005-11-14 2007-05-16 4Sc Ag Thiazole analogues and uses thereof
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
US20090076075A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
WO2007099335A1 (en) * 2006-03-02 2007-09-07 Astrazeneca Ab Quinoline derivatives for treating cancer
WO2007113548A1 (en) * 2006-04-06 2007-10-11 Astrazeneca Ab Naphthyridine derivatives
US20070258976A1 (en) * 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2149565A1 (de) 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
CA2822491C (en) * 2011-01-21 2023-02-14 Basilea Pharmaceutica Ag Bubr1 as a biomarker for furazanobenzimidazoles
JP6669499B2 (ja) 2013-02-15 2020-03-18 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
JP2016510000A (ja) 2013-02-20 2016-04-04 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物およびその使用
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20190051010A (ko) 2016-09-08 2019-05-14 칼라 파마슈티컬스, 인크. 치료 화합물의 결정형 및 그의 용도
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709479B1 (en) 1999-09-21 2010-05-04 Astrazeneca Quinazoline derivatives and their use as pharmaceuticals
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
ATE394102T1 (de) 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
WO2003000188A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
ES2290529T3 (es) * 2002-12-24 2008-02-16 Astrazeneca Ab Derivados de fosfonooxiquinazolina y su uso farmaceutico.
JP2006512387A (ja) * 2002-12-24 2006-04-13 アストラゼネカ アクチボラグ 化合物

Also Published As

Publication number Publication date
US7407946B2 (en) 2008-08-05
WO2004058752A1 (en) 2004-07-15
CA2508921A1 (en) 2004-07-15
CN1753889A (zh) 2006-03-29
KR20050087863A (ko) 2005-08-31
ZA200504828B (en) 2008-02-27
US20060058523A1 (en) 2006-03-16
BR0317680A (pt) 2005-11-29
JP2006516138A (ja) 2006-06-22
AU2003290322A1 (en) 2004-07-22
MXPA05006920A (es) 2006-02-10
NO20052991L (no) 2005-07-19
EP1575946A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
DK1474420T3 (da) Quinazolinforbindelser
NO20052991D0 (no) Kinazolinforbindelser.
DK1667992T3 (da) Quinazolinderivater
NO20053248D0 (no) Kerosenblanding.
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
NO20052248D0 (no) Svivelstykkesystem.
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
ITMI20032170A1 (it) Tagliacimosse.
NO20051497D0 (no) Beta-laktamaseinhibitorprodrug.
ITMI20030916A1 (it) Lancetta.
ES1052590Y (es) Quiosco-consigna.
ES1051703Y (es) Potera.
ES1052945Y (es) Contraventana.
ES1052938Y (es) Cantonera.
ES1052654Y (es) Cubitera.
ES1052029Y (es) Balin-proyectil.
ES1052011Y (es) Espetero.
ES1051605Y (es) Cromo-puzzle.
ES1051110Y (es) Caja-palet.
ITVI20020277A1 (it) Salvapenne.
ITRE20020089A1 (it) Apparecchiatutto.
ITTO20020864A1 (it) Salvapolsino.
NL1020250A1 (nl) Stelwig.
ITTO20020722A1 (it) Alchinilcarbossi-nucleotidi.
ITRM20020327A1 (it) Dnaser.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application